Great Basin Attends ASM Microbe 2016 to Transform the Way Hospitals Diagnose Infectious Disease

Three Featured Posters Validate the Company’s Newly-Cleared Staph ID/R Blood Culture Panel and Shiga Toxin Direct Molecular Assays

 

SALT LAKE CITY--- Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, announced today it is bringing its innovative solution to ASM Microbe 2016 in Boston, Mass., June 17-20 to help small to medium-sized hospitals learn more about the company's cost-effective, sample-to-result platform to reduce costs, increase efficiency and provide better patient outcomes. ASM Microbe 2016—integrating the American Society for Microbiology’s two premier events, the General Meeting and ICAAC—showcases the best microbial sciences in the world and provides a one-of-a-kind forum to explore the complete spectrum of microbiology, from basic science to translation and application. Great Basin will be exhibiting in booth 219, where ASM attendees can receive one-on-one demonstrations of the platform and schedule meetings with Product and Sales team leaders.

“We are pleased to be able to present the benefits of our diagnostic platform and unique customer-centric business model to a larger audience, and are excited to meet new users at ASM this year,” said Sandra Nielsen, senior vice president of sales and marketing, human resources of Great Basin Scientific. “Our exceptional customer growth and the ongoing positive feedback from our users are indicative of the overwhelming need in the market for an innovative solution like ours. Great Basin can uniquely offer low cost, ease-of-use and versatility in a molecular diagnostic system that so many U.S. hospitals and clinics desperately need.”

 

In addition to the exhibition, the Scientific Program has selected posters featuring outcomes by third party researchers using the Great Basin platform. Two posters will be presented with clinical study findings on Great Basin’s Staph ID/R Blood Culture Panel the Company’s first U.S. Food & Drug Administration (FDA)-cleared multiplex panel:

 

Poster# MONDAY-086: Multi-Center Evaluation of the Portrait Staph ID/R Blood Culture Panel, G. Denys, S. Young, J. Daly, M. Couturier, B. Buchan, N. Ledeboer, shows the evaluation of the performance of the Staph ID/R Panel compared to standard reference methods. Researchers found the performance characteristics of the Panel compared favorably to reference methods, and the that the multiplex amplification assay provides valuable information beyond the initial Gram stain in less than two hours of testing. The findings concluded that the Panel’s accurate and rapid organism identification and resistance mechanism could have a positive impact on patient management.

Poster# MONDAY-083: Evaluation of the Portrait Staph ID/R Blood Culture Panel in Pediatric and Adult Patient Populations, A. Hopper, M. V. Powers-Fletcher, S. Holt, A. Phillips, R. Grand-Pre, M. Dickie, A. Blaschke, M. R. Couturier, J. A. Daly, shows that the panel performs with high sensitivity and specificity for the identification of Staphylococcus species and detection of mecA, compared to standard culture and molecular study methods. The poster states that implementation of this methodology in clinical laboratories could allow for accurate and more rapid identification of blood stream infections caused by methicillin-resistant staphylococci, and thus improve patient care.

Outcomes of a multi-center clinical evaluation on Great Basin’s Shiga Toxin Direct Test —the only FDA-cleared standalone molecular test enabling the fast, precise detection of STEC—will also be presented:

 

Poster# MONDAY-197: Evaluation of the Great Basin Shiga Toxin Direct Molecular Assay for the Detection of Shiga-like Toxin Producing Escherichia coli (STEC) in Diarrheal Stool Specimens, M. L. Faron, N. A. Ledeboer, J. Connolly, P. A. Granato, J. Dien Bard, J. A. Daly, S. Young, B. W. Buchan, shows the assay is 100 percent sensitive for detection of STEC, including serotype O:157, compared to culture and enzyme-linked immunosorbent assay (EIA) test. The study found ST Direct identified an additional eight specimens, including two serotype O:157, that were missed by culture. Compared to ST Direct, EIA is only 33 percent sensitive for detection of STEC. Culture is insensitive for the detection of O:157.

“The results of the studies being shared with the attendees at ASM Microbe 2016 validate Great Basin’s hard work to meet the needs of our customers by creating tests that are not only easy to do and provide fast, actionable results for life threatening diseases, but also perform with excellent sensitivity and specificity in the clinical setting,” said Robert D. Jenison, chief technology officer, Great Basin Scientific. “We continue to strive to provide diagnostic solutions that provide faster results to aid in directing appropriate treatments, contributing to improved patient care and outcomes. Additionally, all of our current and future assays work with our benchtop analyzer, making our solution efficient and cost-effective for the small and mid-sized hospital customers we serve.”

 

Posters will be available after ASM Microbe 2016 on the Great Basin website at www.gbscience.com, or on ASM’s website,http://www.asmmicrobe.org/images/AbstractsPull_6-1.pdf.

 

About ASM

 

The American Society for Microbiology (ASM) is the largest single life science society, composed of over 47,000 scientists and health professionals. ASM's mission is to promote and advance the microbial sciences.

 

ASM advances the microbial sciences through conferences, publications, certifications and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences. For more information about ASM, please visit http://www.asm.org/.

 

About Great Basin Scientific

 

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at www.gbscience.com.

 

Forward-Looking Statements

 

This press release includes forward-looking statements regarding the Company’s continuing business efforts related to its products, including but not limited to, presentation at the ASM, the potential market for the Company’s products, the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases and related statements. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history of losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company’s filings with the Securities and Exchange Commission, including the risks set forth in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

 

 

View source version on businesswire.com:http://www.businesswire.com/news/home/20160609005629/en/

 

Contact:

Media:

ICR

Kate Ottavio Kent, 203.682.8276

This email address is being protected from spambots. You need JavaScript enabled to view it.

or

Investor Relations:

Corprominence

Scott Gordon, 516.222.2560

This email address is being protected from spambots. You need JavaScript enabled to view it.

or

ICR

David Clair, 646.277.1266

This email address is being protected from spambots. You need JavaScript enabled to view it.